Nuvation Bio Inc.

Nuvation Bio Inc. (NUVB) is a clinical-stage oncology biopharmaceutical company that completed its business combination with Panacea Acquisition Corp. II, sponsored by Panacea Acquisition Management II LLC, in February 2021. The blank-check vehicle, which conducted its IPO in 2020, targeted the healthcare and life sciences sector. Founded by veteran oncology entrepreneur David Hung, Nuvation Bio is focused on developing next-generation cancer therapies designed to overcome mechanisms of tumor resistance. The 10-K/A filing, submitted in May 2021, represents an amendment to the company's initial annual report following the close of the de-SPAC transaction. Readers seeking comprehensive filing history, sponsor details, and deal analytics for NUVB and thousands of other SPACs can sign up for full data access at SpacDesk.